Kuramoto K, Matsushita S
Jpn Circ J. 1985 Nov;49(11):1144-50. doi: 10.1253/jcj.49.1144.
In order to examine the effect of treatment of mild hypertension of the aged, a 4 year prospective trial was performed in 41 placebo and 38 drug-treated patients with an average age of 76.5 years. Patients were matched for blood pressure, sex and age. Patients with cardiovascular complications or blood pressure elevation above 200/110 were categorized as dropouts and totaled 17 cases (41.5%) in the placebo group, and 4 cases (10.5%) in the drug-treated group (p less than 0.01). In diastolic hypertension, dropouts formed 63.6% of the placebo group (mean BP, 170/92), and 9.5% of the drug group (mean BP, 179/94) (p less than 0.001). In systolic hypertension, dropouts were of 15.8% in the placebo group (mean BP, 164/79), and of 11.8% in the drug group (mean BP, 167/79), and no significant difference was observed. In the placebo group, dropouts were significantly higher in patients with pretreatment systolic blood pressure over 170 mmHg or diastolic blood pressure over 90 mmHg. In patients of 75 years of age or more, dropouts were 46.4% in the placebo group, and 13.0% in the drug treated group showing the beneficial effect of drug treatment even in those over the age of 75. However, no beneficial effect was observed over the age of 85. Stepwise multiple regression analysis of total case revealed that the greatest predictor for dropout was the presence of placebo (i.e. no treatment), explaining 12.2% of the variation in future dropout. Similarly, diastolic hypertension explained 7.5%, creatinine 6.7%, and age 4.6% of this variation.(ABSTRACT TRUNCATED AT 250 WORDS)
为研究老年轻度高血压的治疗效果,对41例服用安慰剂和38例接受药物治疗的患者进行了一项为期4年的前瞻性试验,患者平均年龄为76.5岁。患者在血压、性别和年龄方面进行了匹配。患有心血管并发症或血压高于200/110的患者被归类为失访者,安慰剂组有17例(41.5%),药物治疗组有4例(10.5%)(p<0.01)。在舒张期高血压患者中,失访者占安慰剂组的63.6%(平均血压170/92),药物治疗组的9.5%(平均血压179/94)(p<0.001)。在收缩期高血压患者中,安慰剂组失访者占15.8%(平均血压164/79),药物治疗组占11.8%(平均血压167/79),未观察到显著差异。在安慰剂组中,治疗前收缩压超过170 mmHg或舒张压超过90 mmHg的患者失访率显著更高。在75岁及以上的患者中,安慰剂组失访率为46.4%,药物治疗组为13.0%,表明药物治疗即使在75岁以上患者中也有有益效果。然而,85岁以上患者未观察到有益效果。对所有病例进行的逐步多元回归分析显示,失访的最大预测因素是服用安慰剂(即未治疗),解释了未来失访变异的12.2%。同样,舒张期高血压解释了该变异的7.5%,肌酐解释了6.7%,年龄解释了4.6%。(摘要截短于250字)